Welcome

Welcome to the CLL Clinical Roadmap chaired by Dr. Susan O'Brien and Dr. John Gribben. The CLL Roadmap is a free to access educational curriculum featuring presentations from world leading experts in their field. Every month we will have guest speakers presenting findings on a hot topic and the chairs will join to participate in a debate and question and answers session to dive deep into the subject.

Please register below to get free access to the content and to receive the monthly webinar direct to your email.

Co-chairs

Susan O'Brien MD

University of California Irvine Medical Center, USA

Prof. John Gribben MD

Barts Cancer Institute, London, UK

January

Othman Al-Sawaf MD

University of Cologne, Germany

Venetoclax pivotal trials, latest data:
CLL 14 Update

John Seymour MD

Peter MacCallum Cancer Centre, Melbourne, Australia

Venetociax pivotal trials, latest data: Murano Update

February

Jacqueline Barrientos MD

Feinstein Institutes for Medical Research, New York, USA

Long term follow-up on approved BTKi
in CLL: Ibrutiniba

Paolo Ghia MD

Università Vita-Salute San Raffaele, Milan, Italy

Recent advances in lymphoma clinical trials

March

Carol Moreno MD

Hospital de Sant Pau i Santa Creu, Barcelona, Spain

PKI3 inhibitors in CLL: Idelalisib + Rituximab

Ian Flinn MD

Tennessee Oncology, Nashville, USA

PKI3 inhibitors in CLL: Duvelisib

April

Jennifer Brown MD

Dana-Farber Cancer Institute, Boston, USA

Agents close to approval in CLL: Zanubrutinib

John Gribben MD

Barts Cancer Institute, London, UK

Agents close to approval in CLL: Umbralisib

January

Othman Al-Sawaf MD

University of Cologne, Germany

Venetoclax pivotal trials, latest data:
CLL 14 Update

John Seymour MD

Peter MacCallum Cancer Centre, Melbourne, Australia

Venetociax pivotal trials, latest data: Murano Update

February

Jacqueline Barrientos MD

Feinstein Institutes for Medical Research, New York, USA

Long term follow-up on approved BTKi
in CLL: Ibrutiniba

Paolo Ghia MD

Università Vita-Salute San Raffaele, Milan, Italy

Recent advances in lymphoma clinical trials

March

Carol Moreno MD

Hospital de Sant Pau i Santa Creu, Barcelona, Spain

PKI3 inhibitors in CLL: Idelalisib + Rituximab

Ian Flinn MD

Tennessee Oncology, Nashville, USA

PKI3 inhibitors in CLL: Duvelisib

April

Jennifer Brown MD

Dana-Farber Cancer Institute, Boston, USA

Agents close to approval in CLL: Zanubrutinib

John Gribben MD

Barts Cancer Institute, London, UK

Agents close to approval in CLL: Umbralisib

May

Jennifer Woyach MD

The Ohio State University Comprehensive Cancer Centre, Columbus, USA

Non-covalent BTK inhibitors: ARQ

Wojciech Jurczak MD

Maria Sklodowska-Curie National Reseach Institute of Oncology, Krakow, Poland

Non-covalent BTK inhibitors: LOXO

June

Deborah Stephens MD

Huntsman Cancer Institute, University of Utah, USA

High Risk CLL: Therapy

Stephan Stilgenbauer MD

Ulm University, Germany

High Risk CLL: Biology

July

Tanya Siddiqi MD

City of Hope, California, USA

CART in CLL

Peter Dreger MD

University of Heidelberg, Germany

Allo SCT in CLL

August

Andy Rawstron MD

Leeds Teaching Hospitals NHS Trust, UK

MRD: Methodology

Carolyn Owen MD

University of Calgary, Canada

MRD: Clinical importance

May

Jennifer Woyach MD

The Ohio State University Comprehensive Cancer Centre, Columbus, USA

Non-covalent BTK inhibitors: ARQ

Wojciech Jurczak MD

Maria Sklodowska-Curie National Reseach Institute of Oncology, Krakow, Poland

Non-covalent BTK inhibitors: LOXO

June

Deborah Stephens MD

Huntsman Cancer Institute, University of Utah, USA

High Risk CLL: Therapy

Stephan Stilgenbauer MD

Ulm University, Germany

High Risk CLL: Biology

September

Bill Wierda MD

MD Anderson Cancer Center, Houston, Texas, USA

There is still a role for Chemoimmunotherapy in CLL

Barbara Eichhorst MD

University Hospital Cologne, Germany

There is no role for Chemoimmunotherapy in CLL

October

Arnon Kater MD

University of Amsterdam, The Netherlands

Sequencing BTKi and Venetoclax

Anthony Mato MD

Memorial Sloan Kettering Cancer Center, New York, USA

Real World Data with Venetoclax

November

Davide Rossi MD

Institute of Oncology Research, Bellinzona, Switzerland

Richters syndrome: Richters Biology

Nicole Lamanna MD

Columbia University Herbert Irving Comprehensive Cancer Center, USA

Richters syndrome: Richters Therapy

December

Susan O’Brien MD

University of California Irvine Medical Center, USA

Next Questions in CLL

Anna Schuh MD

University of Oxford, UK

NGS in CLL, what does it add

July

Tanya Siddiqi MD

City of Hope, California, USA

CART in CLL

Peter Dreger MD

University of Heidelberg, Germany

Allo SCT in CLL

August

Andy Rawstron MD

Leeds Teaching Hospitals NHS Trust, UK

MRD: Methodology

Carolyn Owen MD

University of Calgary, Canada

MRD: Clinical importance

September

Bill Wierda MD

MD Anderson Cancer Center, Houston, Texas, USA

There is still a role for Chemoimmunotherapy in CLL

Barbara Eichhorst MD

University Hospital Cologne, Germany

There is no role for Chemoimmunotherapy in CLL

October

Arnon Kater MD

University of Amsterdam, The Netherlands

Sequencing BTKi and Venetoclax

Anthony Mato MD

Memorial Sloan Kettering Cancer Center, New York, USA

Real World Data with Venetoclax

November

Davide Rossi MD

Institute of Oncology Research, Bellinzona, Switzerland

Richters syndrome: Richters Biology

Nicole Lamanna MD

Columbia University Herbert Irving Comprehensive Cancer Center, USA

Richters syndrome: Richters Therapy

December

Susan O’Brien MD

University of California Irvine Medical Center, USA

Next Questions in CLL

Anna Schuh MD

University of Oxford, UK

NGS in CLL, what does it add

Every month one of the co-chairs, Susan O'Brien or John Gribben, and two guest speakers will dive deep into hot topics and have an open debate on current issues within the CLL field.

Each expert presentation is followed by a question and answer session with one of the co-chairs and includes downloadable slides to enhance understanding.

Susan O'Brien, M.D

University of California Irvine Medical Center, USA

Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of New Jersey. She served there as an instructor in medicine before moving to California, where she served as an instructor in the San Fernando Valley Program in the University of California, Los Angeles School of Medicine and an internist in the University of Southern California Student Health Service. During her time at MD Anderson, Dr. O’Brien has been the principal investigator or a co-principal investigator for 5 funded research projects and the primary investigator for more than 20 funded protocols. In addition, she has served on the Translational Research Study Section for the Leukemia and Lymphoma Society since 2001.

Prof. John Gribben

Barts Cancer Institute, London, UK

Dr. John Gribben is a professor and medical oncologist at Barts Cancer Institute in London, United Kingdom. He specializes in hematology/oncology; lymphoma; chronic lymphocytic leukemia; and bone marrow transplantation. Dr. Gribben received his medical training from the University of Glasgow, University College London and Harvard Medical School. He is a member of the CLL Research Consortium and has more than 200 peer-reviewed articles in medical journals.

Ian Flinn Presentation

Ian Flinn Overview

Ian Flinn PDF presentation download

Carol Moreno Presentation

Carol Moreno Overview

Carol Moreno PDF presentation download

Jennifer Brown – Presentation

Jennifer Brown – Overview

John Gribben- Presentation

John Gribben – Overview

Faculty Q&A

[iframe src="https://cllroadmap.md-education.com/?lesson=july-video" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/lesson/december-video-2/" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/lesson/may-2/" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/?lesson=december-video-1/" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/?lesson=october-video" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/?lesson=august-video" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/?lesson=november-video" width="100%" height="750" scrolling="no" ]
[iframe src="https://cllroadmap.md-education.com/?lesson=june-video" width="100%" height="750" scrolling="no" ]

Jennifer Woyach Presentation

Jennifer Woyach Overview

Jennifer Woyach presentation

Wojciech Jurczak Presentation

Wojciech Jurczak Overview

Wojciech Jurczak presentation

Faculty Q&A